GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation

GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France

GenSight Biologics announces a financing for an amount of c. €2.8 million from existing investors

GenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ®

GenSight Biologics Reports Cash Position as of September 30, 2024, and Provides Business Update

GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024

GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates

GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update

GenSight Biologics Launches Newsletter for Retail Investors

GenSight Biologics renegotiates financial obligations and provides operational updates